Finding new drug targets for liver cancer treatment
CRISPR and Humanized mice-based Discovery of a Novel Drug target for HCC Therapy
['FUNDING_R21'] · UNIVERSITY OF ALABAMA AT BIRMINGHAM · NIH-11030261
This study is looking for new ways to treat liver cancer by finding out what helps tumors grow and how we can stop them, so that patients can have better treatment options in the future.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ALABAMA AT BIRMINGHAM (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11030261 on ClinicalTrials.gov |
What this research studies
This research investigates new therapeutic targets for hepatocellular carcinoma (HCC), the most common type of liver cancer. By using advanced techniques like CRISPR and humanized mouse models, the study aims to identify factors that promote tumor growth and how to effectively inhibit them. The approach focuses on overcoming limitations of traditional drug discovery methods, which often fail to translate effectively to human treatments. Patients may benefit from the identification of new, more effective therapies for advanced liver cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced hepatocellular carcinoma who have limited treatment options.
Not a fit: Patients with early-stage liver cancer or those who do not have hepatocellular carcinoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective treatments for patients with advanced liver cancer.
How similar studies have performed: Other research has shown promise in using CRISPR and humanized models for drug target discovery, indicating a potential for success in this novel approach.
Where this research is happening
BIRMINGHAM, UNITED STATES
- UNIVERSITY OF ALABAMA AT BIRMINGHAM — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WAJAPEYEE, NARENDRA — UNIVERSITY OF ALABAMA AT BIRMINGHAM
- Study coordinator: WAJAPEYEE, NARENDRA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Anti-Cancer Agents, anti-cancer drug